None listed
Conditions
Interventions
Drug : Each arm will be allocated 1:1 ratio by ranomization, Placebo/DA-9701 will be descripted for 8weeks. Wash out period is 4weeks.
After finishing wash-out period each subject will be changed Plac
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. age : 18-65 2. Postural Orthostatic Tachycardia Syndrome 3. Not intake prokinetics((itopride, gasmotin, corydalis tuber, levosulpride,domperidone etc) within 2months 4. Having symptoms like as below Loss of appetite, Retching, abdominal distention, indigestion, early satiety, dysphagia, Foreign body sensation at neck and pharingolaryngeal, Gastroesophageal reflux, nausea/vomitting
Exclusion criteria
Exclusion criteria: 1. Current of previous history of structural heart disease or arrhythmia 2. Current of previous history of Thyroid diseas or Adrenal disease 3. Other systemic conditions including ; infection disease, auto-immune disease, COPD, hepatitis and liver cirrhosis, acute cardiac failure or MI, pernicious anemia,acute respiratory disease etc, 4. Pregnant or breast-feeding subject 5. Subject who has inappropriate medical condition for entry into this study by investigator's judgement. 6. Known prior hypersensitivity to DA-9701 7. Known joining other study of gastorintestinal investigational product within 3months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NDI-K (Korean Nepean Dyspepsia Index) Score | — |
Secondary
| Measure | Time frame |
|---|---|
| SF-36 Score | — |
Countries
Korea, Republic of
Contacts
Public ContactDa-Young Seo
Asan Medical Center
Outcome results
None listed